Short Interest in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Declines By 39.2%

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) was the target of a significant decline in short interest during the month of February. As of February 28th, there was short interest totalling 955,300 shares, a decline of 39.2% from the February 13th total of 1,570,000 shares. Approximately 3.7% of the company’s stock are sold short. Based on an average trading volume of 5,260,000 shares, the days-to-cover ratio is currently 0.2 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Virpax Pharmaceuticals stock. Garden State Investment Advisory Services LLC bought a new stake in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 57,300 shares of the company’s stock, valued at approximately $40,000. Garden State Investment Advisory Services LLC owned approximately 1.17% of Virpax Pharmaceuticals at the end of the most recent quarter. Hedge funds and other institutional investors own 32.23% of the company’s stock.

Virpax Pharmaceuticals Trading Down 6.5 %

VRPX opened at $0.17 on Friday. The business’s 50-day simple moving average is $0.28 and its 200 day simple moving average is $0.48. Virpax Pharmaceuticals has a 52-week low of $0.16 and a 52-week high of $4.83.

About Virpax Pharmaceuticals

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.